04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
00:49 , Sep 9, 2017 |  BioCentury  |  Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
21:34 , Jun 23, 2017 |  BioCentury  |  Emerging Company Profile

TRuCs vs. CARs

TCR2 Therapeutics Inc. is creating autologous T cell therapies that it thinks will have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies. The key to the approach is...
07:00 , Sep 19, 2016 |  BioCentury  |  Emerging Company Profile

Solid CARs

Long-standing doubts about whether CAR T cells would be effective against solid tumors were exacerbated last year after Novartis AG and the University of Pennsylvania reported that their CART-meso showed no complete or partial responses...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Clinical News

CAR-T-meso: Phase I data

Data from 5 patients with mesothelin-expressing tumors in a U.S. Phase I trial showed that a single infusion of 1-3*107 CAR-T-meso cells/m 2 was well tolerated with no off-tumor on-target toxicities reported. Grade 4 adverse...
07:00 , Apr 27, 2015 |  BioCentury  |  Product Development

CAR window

MaxCyte Inc. is collaborating with the Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University to develop transiently expressed chimeric antigen receptor T cell therapies that may allow better control over the cells' therapeutic...
07:00 , Apr 27, 2015 |  BioCentury  |  Finance

CAR talk

While investors in Kite Pharma Inc. (NASDAQ:KITE) and Juno Therapeutics Inc. (NASDAQ:JUNO) will soon be combing through American Society of Clinical Oncology abstracts, they shouldn't hold their breath for efficacy data for the CAR T...
02:19 , Apr 22, 2015 |  BC Extra  |  Company News

MaxCyte, JHU partner for preclinical CARs

MaxCyte Inc. (Gaithersburg, Md.) partnered with The Johns Hopkins University (Baltimore, Md.) to develop chimeric antigen receptor (CAR) T cell therapies to treat solid tumors based on MaxCyte's mRNA technology that results in transient expression...
01:38 , Apr 21, 2015 |  BC Extra  |  Top Story

CAR T stocks fall on solid tumor data

CAR T data from Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Pennsylvania demonstrated much of what's already known about the challenges of moving the technology into the solid tumor setting. A presentation at the...